Categories: Health

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, today announced that Aryeh Batt, Co-Founder and Chief Executive Officer will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 25-26, 2026. The executive team will also be available for one-on-one meetings with investors throughout the conference.

Format: Company Presentation, Live Webcast

Date/Time: Thursday, February 26, 2026, at 8:00 am ET

About Precise Bio

Precise Bio is a clinical-stage regenerative medicine company pioneering tissue engineering using its proprietary 3D-bio-fabrication platform, which integrates cell biology and biomaterials to produce clinical-grade human tissues under GMP conditions. Its lead program, PB-001, is the world’s first bio-printed corneal implant to enter human clinical trials, with additional ophthalmology and advanced tissue programs in development. For more information, visit www.precise-bio.com.

Contact

Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com

GlobeNews Wire

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

1 hour ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

1 hour ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

1 hour ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

1 hour ago